Expressive

rs10953090 - RN7SL7P - SAMD9

Magnitude 4.5 · 1 study on file

Reported associations

  • PPARGC1B Is Associated with Nontraumatic Osteonecrosis of the Femoral Head: A Genomewide Association Study on a Chart-Reviewed Cohort. - The Journal of bone and joint surgery. American volume (2021) · Zhang Y, Bowen TR, Lietman SA, Suk M, Williams MS, Lee MTM · PubMed 32701715

    Previous studies have demonstrated the influence of heritable factors on the development of nontraumatic osteonecrosis of the femoral head (ONFH). We hypothesized that genetic variation is associated with an increased risk of ONFH, and that variants could be identified by a genomewide association study (GWAS). Using data collected from the MyCode Community Health Initiative, we identified 118 adult patients with radiographically confirmed nontraumatic ONFH. Study patients were statistically compared with a control population of 56,811 unrelated individuals without a diagnosis of ONFH. A case-control GWAS was performed to identify single nucleotide variants (SNVs) associated with ONFH. Sensitivity analyses were performed to evaluate the association of the top SNVs with (cortico)steroid-asso

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Discuss with your doctor

  • SAMD9 rs10953090 carrier status before corticosteroid use Moderate

    rs10953090 in SAMD9 confers 2.57-fold increased risk of nontraumatic femoral head osteonecrosis with systemic corticosteroid exposure

    Inform your physician of this genetic variant when corticosteroid treatment is being considered

Lifestyle

  • Limit systemic corticosteroid use Moderate

    SAMD9 rs10953090 carriers have 2.57-fold increased osteonecrosis risk with steroid exposure; minimizing steroid use where possible reduces this risk

    When non-steroid alternatives exist, discuss with your doctor whether they are suitable for your condition

Screening

  • Hip pain and reduced mobility if taking corticosteroids Moderate

    SAMD9 rs10953090 carriers have elevated osteonecrosis risk during steroid therapy; early symptoms include hip pain, groin pain, and limited range of motion

    If prescribed steroids, monitor for hip or groin pain and report any symptoms immediately to your doctor